DOI: 10.1111/eci.14101

#### ORIGINAL ARTICLE

WILEY

# Association between exposure to air pollution and blood lipids in the general population of Spain

Sergio Valdés<sup>1,2</sup> Viyey Doulatram-Gamgaram<sup>1</sup> Cristina Maldonado-Araque<sup>1,2</sup> Marta García-Escobar<sup>1,2</sup> Sara García-Serrano<sup>1,2</sup> Wasima Oualla-Bachiri<sup>1,2</sup> Marta García-Vivanco<sup>3</sup> Juan Luis Garrido<sup>3</sup> Victoria Gil<sup>3</sup> Fernando Martín-Llorente<sup>3</sup> Alfonso Calle-Pascual<sup>2,4</sup> Luis Castaño<sup>2,5,6</sup> Elías Delgado<sup>7</sup> Edelmiro Menéndez<sup>7</sup> Josep Franch-Nadal<sup>2,8</sup> Sonia Gaztambide<sup>2,6,9</sup> Joan Girbés<sup>10</sup> F. Javier Chaves<sup>2,11</sup> José L. Galán-García<sup>12</sup> Gabriel Aguilera-Venegas<sup>12</sup> Joan Carles Vallvé<sup>2,13</sup> Núria Amigó<sup>2,14,15</sup> Montse Guardiola<sup>2,13</sup> Josep Ribalta<sup>2,13</sup> Gemma Rojo-Martínez<sup>1,2</sup>

<sup>1</sup>Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga/Universidad de Málaga, Instituto de Investigación Biomedica de Málaga-IBIMA, Málaga, Spain

<sup>2</sup>Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain

<sup>3</sup>Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) – División de Contaminación Atmosférica, Madrid, Spain

<sup>4</sup>Department of Endocrinology and Nutrition and Instituto de Investigación Sanitaria University Hospital S. Carlos (IdISSC), Department Medicine II, Universidad Complutense (UCM), Madrid, Spain

<sup>5</sup>Hospital Universitario Cruces, BioCruces, UPV/EHU, Barakaldo, Spain

<sup>6</sup>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

<sup>7</sup>Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias/University of Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

<sup>8</sup>EAP Raval Sud, Institut Català de la Salut, Red GEDAPS, Primary Care, Unitat de Suport a la Recerca (IDIAP – Fundació Jordi Gol), Barcelona, Spain

<sup>9</sup>Department of Endocrinology and Nutrition, Hospital Universitario Cruces – BioCruces Bizkaia – UPV-EHU, Baracaldo, Barcelona, Spain

<sup>10</sup>Diabetes Unit, Hospital Arnau de Vilanova, Valencia, Spain

<sup>11</sup>Genomic Studies and Genetic Diagnosis Unit, Fundación de Investigación del Hospital Clínico de Valencia – INCLIVA, Valencia, Spain

<sup>12</sup>Department of Applied Mathematics, University of Málaga, Málaga, Spain

<sup>13</sup>Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Rovira i Virgili University, IISPV, Reus, Spain

<sup>14</sup>Metabolomics Platform, Universitat Rovira i Virgili, IISRV, Reus, Spain

<sup>15</sup>Biosfer Teslab, Reus, Spain

Valdés Sergio and Doulatram-Gamgaram Viyey have contributed equally to this work and share first authorship.

Josep Ribalta and Gemma Rojo-Martínez have contributed equally to this work and share last authorship.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

# <sup>2 of 11</sup> | −WIL

#### Correspondence

Sergio Valdés, Department of Endocrinology and Nutrition, Hospital Universitario Regional de Málaga Plaza del Hospital Civil s/n, 29009 Málaga, Spain.

Email: sergio.valdes@hotmail.es

#### **Funding information**

Consejería de Salud y Bienestar Social, Junta de Andalucía, Grant/Award Number: RC-0006-2016; Instituto de Salud Carlos III, Grant/Award Number: CM21/00214, INT21/00037, PI17/02136 and PI20/01322

#### Abstract

**Background and Aims:** We aimed to assess the associations of exposure to air pollutants and standard and advanced lipoprotein measures, in a nationwide sample representative of the adult population of Spain.

**Methods:** We included 4647 adults (>18 years), participants in the national, cross-sectional, population-based di@bet.es study, conducted in 2008–2010. Standard lipid measurements were analysed on an Architect C8000 Analyzer (Abbott Laboratories SA). Lipoprotein analysis was made by an advanced <sup>1</sup>H-NMR lipoprotein test (Liposcale<sup>®</sup>). Participants were assigned air pollution concentrations for particulate matter <10 µm (PM<sub>10</sub>), <2.5 µm (PM<sub>2.5</sub>) and nitrogen dioxide (NO<sub>2</sub>), corresponding to the health examination year, obtained by modelling combined with measurements taken at air quality stations (CHIMERE chemistry-transport model).

**Results:** In multivariate linear regression models, each IQR increase in  $PM_{10}$ ,  $PM_{2.5}$  and  $NO_2$  was associated with 3.3%, 3.3% and 3% lower levels of HDL-c and 1.3%, 1.4% and 1.1% lower HDL particle (HDL-p) concentrations (p < .001 for all associations). In multivariate logistic regression, there was a significant association between  $PM_{10}$ ,  $PM_{2.5}$  and  $NO_2$  concentrations and the odds of presenting low HDL-c (<40 mg/dL), low HDL-p (<p25) and higher LDL particle (LDL-p) concentrations ( $\geq p75$ ). In subgroup analyses there were stronger associations between  $PM_{10}$  and  $NO_2$  and low HDL-p in men (p for interaction .008 and .034), and between  $NO_2$  and low HDL-p in individuals with obesity (p for interaction .015). **Conclusions:** Our study shows an association between the exposure to air pollutants and blood lipids in the general population of Spain, suggesting a link to atherosclerosis.

#### K E Y W O R D S

air pollution, cholesterol, HDL, lipids, lipoprotein, triglyceride

# 1 | BACKGROUND

The World Health Organization (WHO) has identified air pollution as the largest single environmental health risk worldwide, with outdoor air pollution accounting for more than 4.2 million deaths every year.<sup>1</sup> Nearly half of outdoor air pollution-related premature deaths are due to ischaemic heart disease and stroke.<sup>1</sup> Air pollution can impact the cardiovascular system through a number of mechanisms, including endothelial dysfunction, systemic and pulmonary oxidative stress and inflammation, autonomic nervous system dysfunction and epigenetic changes.<sup>2-5</sup> Alterations in lipid metabolism could be another potential pathway in the association between air pollution and arteriosclerosis. In this regard, several previous epidemiological studies have explored the relationships between the exposure to several ambient air pollutants and blood lipid levels and the presence of dyslipidaemia.<sup>6–24</sup> However, most of this evidence has relied on standard lipid measures. Standard lipid panels measure the cholesterol or triglyceride content (in concentration per decilitre) carried by each lipoprotein class, rather than the numbers of these particles. In contrast, NMR spectroscopy provides a direct assessment of the number and size of lipoprotein particles, providing additional information about cardiovascular disease (CVD) risk.<sup>25–29</sup>

Accordingly, in the present study, we aimed to assess the associations between the exposure to air pollutants [particles with an aerodynamic diameter of less than 10 microns ( $PM_{10}$ ), particles with an aerodynamic diameter of less than 2.5 microns ( $PM_{2.5}$ ) and nitrogen dioxide ( $NO_2$ )], with both the blood lipid levels of a standard lipid profile as well as the particle concentrations of lipoproteins, in a nationwide sample representative of the adult population of Spain.

#### VALDÉS ET AL.

# WILEY $\frac{|3 \text{ of } 11}{|3 \text{ of } 11|}$

## 2 | METHODS

# 2.1 | Study design, setting and population

The Di@bet.es study is a national, cross-sectional, population-based survey conducted in 2008–2010.<sup>30</sup> A cluster sampling design was used to select participants to form a representative random sample of the Spanish population. One hundred health centres or their equivalent from all around the country were selected at random, with a probability for selection proportional to their target population size, after which 100 individuals aged ≥18 years were randomly selected from each health centre. Of the eligible adults, 55.8% came for examination, of which 9.9% were excluded (institutionalized, severe disease, pregnancy or recent delivery), resulting in a final sample of 5072 individuals.

The present study focuses on 4647 individuals (92% of the study sample), in whom complete data on concentrations of air pollutants and blood lipids were available for analyses.

This research was carried out in accordance with the Declaration of Helsinki of the World Medical Association.<sup>31</sup> Written informed consent was obtained from all the participants. The study was approved by the Ethics and Clinical Investigation Committee of the Hospital Regional Universitario de Málaga (Málaga, Spain) in addition to other regional ethics and clinical investigation committees all over Spain.

#### 2.2 | Variables and procedures

The participants were invited to attend a single examination visit at their health centre. Information was collected by means of an interviewer-administered structured questionnaire, followed by a physical examination and blood sampling. Information on age, gender, educational level (none/basic/high school/college), smoking habit (current, former or never smokers) and alcohol intake (<30/30-60/>60 servings per month), was obtained by questionnaire. Food consumption was determined by a food frequency questionnaire and adherence to the Mediterranean diet was estimated by an adaptation of a 14-item Mediterranean diet score (MedScore).<sup>32</sup> The level of daily physical activity was estimated by the short form of the International Physical Activity Questionnaire (IPAQ).<sup>33</sup> Weight and height were measured and the body mass index (BMI) was calculated as weight  $(kg)/height (m)^2$ . Medical history and medications were also recorded.

Blood samples, obtained in fasting conditions, were immediately centrifuged and the serum was frozen until analysis. Samples were managed by the biochemistry laboratory of the Hospital Regional Universitario de Málaga, the IBIMA Biobank and by the CIBERDEM Biorepository (IDIBAPS Biobank).

### 2.3 | Lipid measurements

Standard lipid measurements Serum levels (mg/dL) of triglycerides (TG), total cholesterol (TC) and highdensity lipoprotein cholesterol (HDL-c) were measured on an Architect C8000 Analyzer (Abbott Laboratories SA). Low-density lipoprotein cholesterol (LDL-c) was estimated by the Friedewald formula. 'High total cholesterol' was defined as TC  $\geq$  240 mg/dL; 'high LDL-c' was defined as LDL-c $\geq$  160 mg/dL; 'low HDL-c' was defined as HDL-c < 40 mg/dL; and hypertriglyceridaemia was defined as TG  $\geq$  200 mg/dL.<sup>34</sup>

Lipoprotein analysis Lipoprotein analysis was performed by using Liposcale® Test (CE, ISO 13.485 approved), an advanced lipoprotein test based on twodimensional (2D) diffusion-ordered <sup>1</sup>H-NMR (Proton nuclear magnetic resonance) spectroscopy.<sup>35</sup> Before <sup>1</sup>H-NMR analysis, 200 µL of serum were diluted with 50 µL deuterated water and  $300 \,\mu\text{L}$  of  $50 \,\text{mM}$  phosphate buffer solution at pH7.4. <sup>1</sup>H-NMR spectra were recorded at 306K on a Bruker Avance III 600 spectrometer operating at a proton frequency of 600.20 MHz. The methyl signal was deconvoluted by using Lorentzian functions to determine the lipid concentration of the main lipoprotein classes (VLDL, LDL and HDL), and their size associated diffusion coefficients. Then, the lipid concentrations were combined with their associated particle volume in order to quantify the number of particles required to transport the measured lipid concentration of each lipoprotein subclass calculating the particle concentrations of VLDL (VLDL-p), LDL (LDL-p) and HDL (HDL-p). The variation coefficients for particle number were between 2% and 4%, and for the particle sizes were lower than 0.3%. These analyses were performed at the Biosfer Teslab facilities. We classified participants as having normal or abnormal levels of LDL-p, VLDL-p and HDL-p, using the equivalents of the 75th (LDL-p and VLDL-p) and 25th (HDL-p) percentiles (p) of particle concentrations within our study population.

#### 2.4 | Exposure assessment

Modelled mean annual  $PM_{10}$ ,  $PM_{2.5}$  and  $NO_2$  concentrations in Spain for the period 2008–2010 were calculated with the CHIMERE chemistry-transport model.<sup>36</sup> This model calculates the concentration of gaseous species and both inorganic and organic aerosols of primary and

WILEY

secondary origin, including primary particulate matter, mineral dust, sulphate, nitrate, ammonium, secondary organic species and water. This model has been broadly evaluated in Spain by comparison with measured air pollutants at a large set of monitoring sites.<sup>37,38</sup> The model was applied to a domain covering the Iberian Peninsula at a horizontal resolution of  $0.1 \times 0.1^\circ$ . The modelled concentrations were corrected with observed values, by considering a methodology described by Martín et al.<sup>39</sup> in which (1)a bias is calculated with regard to the observations in the Spanish air quality network of monitoring sites, (2) these biases are spatially interpolated using a kriging methodology to obtain a gridded bias and (3) this gridded bias is applied to the modelled concentration grid. This methodology considers a different bias grid for rural and urban sites that are then combined and weighted by population density. We assigned the average annual exposure to air pollutants corresponding to the health examination year of each participant by interpolating the estimated concentrations to the centroid of their residential postal codes.

Data on mean annual temperature (°C) from each municipality of residence were obtained from the Spanish National Meteorological Agency.<sup>40</sup>

#### 2.5 | Statistical analysis

We applied linear regression models to assess associations between air pollutant and lipid measurements, which were log transformed to normalize distributions and also to limit the influence of extreme values. Association estimates were presented as percent changes with corresponding 95% confidence intervals (calculated by  $100 \times [\exp(b) - 1]$ ), per each interquartile range (IQR) increase in air pollutant concentrations which equated to  $7.7 \,\mu\text{g/m}^3 \text{PM}_{10}$ ,  $4.8 \,\mu\text{g/m}^3 \text{PM}_{2.5}$  and  $12.1 \,\mu\text{g/m}^3 \text{NO}_2$ .

We also used logistic regression models to investigate the associations of ambient air pollutants with high total cholesterol(TC  $\geq$  240 mg/dL); high LDL-c(LDL-c  $\geq$  160 mg/ dL); low HDL-c (HDL-c < 40 mg/dL); and hypertriglyceridaemia (TG  $\geq$  200 mg/dL) as defined by the standard lipid measurements, and with high LDL-p and VLDL-p concentrations ( $\geq$  p75), and low HDL-p concentrations (< p25), measured by the Liposcale<sup>®</sup> test. These results are presented as odds ratios (ORs) with corresponding 95% CIs again per each IQR increase in air pollutants.

All these models were controlled for possible confounders such as age, sex, BMI, education level, smoking status, alcohol intake, municipality population, MedScore, IPAQ, mean ambient temperature of the municipality and lipid lowering medication.

In addition, we investigated potential effect modification of the associations by sex (male/female), age  $(<40/40-60 \text{ or } \ge 60 \text{ years})$  and BMI  $(<30 \text{ or } \ge 30 \text{ kg/m}^2)$ . Each potential modifier was examined in a separate model by adding an interaction term.

All the statistical analyses were performed with IBM SPSS statistics 23.0. Reported *p* values were based on twosided tests with statistical significance set at .05. Bonferroni correction for multiple comparisons was applied at a level of alpha =.05/7 = .007.

#### 3 | RESULTS

A total of 4647 individuals were included in the analysis (Table 1). The sample was composed of 1976 men (42.5%) and 2671 women (57.5%). Mean age of the population was  $50.5 \pm 17.0$  years (range: 18–93 years). The characteristics of the study population followed a distribution as expected in the Spanish general population. Distributions of standard lipids and NMR particle concentrations are also displayed in the table.

Table 2 summarizes residential estimates of outdoor air pollution concentrations assigned to the study participants in the year of examination. The median (25th–75th percentile)  $PM_{10}$ ,  $PM_{2.5}$  and  $NO_2$  exposure levels were 23.7 (19.6–27.3), 12.2 (10.5–15.3) and 16.6 (12.5–24.6) µg/m<sup>3</sup>, respectively. Most values were within the current European Ambient Air Quality Directive target values (Directive 2008/50/EC).<sup>41</sup>

Table 3 shows the results of the linear correlations between air pollutant concentrations and standard lipid biomarkers (TC, LDL-c, HDL-c and TG) and NMR particle concentrations (LDL-p, VLDL-p and HDL-p), in crude, and multivariate adjusted linear regression models. Greater air pollutant exposures were associated with lower TC and LDL-c concentrations in crude models, but these associations were attenuated after multivariate adjustment. This trend was not observed by NMR analyses. In fact the association between air pollutants and LDL-p although not significant tended to be positive. The three pollutants tested showed a strong and highly significant negative association with HDL-c concentrations in both crude and multivariate models. In the fully adjusted model, an IQR increase in PM<sub>10</sub>, PM<sub>2.5</sub> and NO<sub>2</sub> was associated with 3.3%, 3.3% and 3% lower levels of HDL-c, respectively. The same trend was observed regarding the association between contaminants and the concentration of HDL particles measured by NMR. In the multivariate analysis, each IQR increase in PM<sub>10</sub>, PM<sub>2.5</sub> and NO<sub>2</sub> was associated with 1.3%, 1.4% and 1.1% lower HDL-p. PM<sub>2.5</sub> concentrations also showed a positive association with TG levels in multivariate analyses.

Table 4 shows the crude and multivariate-adjusted ORs for presenting lipid abnormalities in the standard lipid

%Mean + ManAge (years)57.550.5 ± .00Vorman57.550.5 ± .00Suroting23.850.00Age (years)50.0050.00Never50.2050.00Ago (years)73.9050.00Ago (years)14.9050.00Ja-Ga14.9050.00Ja-Ga14.9050.00Ja-Ga14.9050.00Ja-Ga13.0050.00Jali (yado)53.8050.00Jali (yado)53.8050.00Jali (yado)53.8050.00Jali (yado)50.0050.00Jali (yado)60.0050.00Jali (yado)60.0050.00Jali (yado)60.0050.00Jali (yado)50.0050.00Jali (yado)50.0050.00Jali (yado)50.0050.00Jali (yado)50.0050.00Jali (yado)50.0050.00Jali (yado)50.0050.00Jali (yado)50.00 <th>sample (<math>n = 4647</math>).</th> <th></th> <th></th> <th></th>	sample ( $n = 4647$ ).			
Nomen57.5SING23.8Current23.8Former26.0Never50.2Alcohol intake (servings		%	Mean $\pm$ SD	Range
Small       23.8         Current       23.8         Former       26.0         Never       50.2         Alcohol intake (servings-multice)       50.2         30-60       14.9         >60       11.3         Shoop-50,000       27.8         >50,000       23.8         >50,000       23.8         Porturicipality population       27.8         \$50,000       23.8         Postudies       12.8         \$50,000       33.8         Education level       12.8         No studies       12.8         Basic       47.6         High school-college       30.6         BMI (kg/m <sup>2</sup> )       28.0 ± 5.2       12.2-61.3         Mediate score       7.8 ± 1.8       1-13         Physical activity (IPAQ)       28.0 ± 5.2       12.6-13         Icow       42.0	Age (years)		$50.5 \pm 17.0$	18-93
Curver       23.8         Former       26.0         Never       50.2         Al-cohol intake (servings-weiller)       50.2 $30-60$ 14.9 $>60$ 11.3 $>60$ 11.3 $Vuricipality population       27.8         < 10,000       53.8         Education level       50.00         Education level       50.00         Basic       47.6         High school-college       39.6         BMI (kg/m2)       28.0 ± 5.2       12.2-61.3         Med diet score       78 ± 1.8       1-13         Flipsical activity (IPAQ)       78.± 1.8       1-13         Ichw       42.0       50.00       1.2-61.3         Medium       34.5       50.00       50.00         Ichw       42.0       50.00       50.00         Ichw       42.0       50.00       50.00         Ichw       42.0       50.00       50.00         Ichw       42.0       50.00       50.00         Ichy       105.1       50.00       50.00         Ichy       105.1       50.00       50.00         Ichy       $	Women	57.5		
Former       26.0         Never       50.2         Alcohol intake (servings-momentation of the servings of the servings of the servings of the serving of the servine of the service of the servine of the service of the se	Smoking			
Never         50.2           Alcohol intake (servings-work)	Current	23.8		
Alcohol intake (servings-monthermation of the serving	Former	26.0		
<30	Never	50.2		
30-60       14.9         >60       11.3         Hurnicipality population       11.3         <10,000	Alcohol intake (servings-mo	onth)		
>60       11.3         Municipality population          <10,000	<30	73.9		
Numicipality population         <10,000	30-60	14.9		
<10,000	>60	11.3		
10,000-50,00027.8>50,00053.8Education level12.8Mo studies47.6Basic39.6 $BMI (kg/m^2)$ 28.0 ± 5.2 $I2.2$ -61.3Med diet score7.8 ± 1.8Physical activity (IPAQ)Low42.0Medium34.5High23.5Lipid lowering medication13.3TC196 ± 40TC196 ± 40LDL-C105 ± 30LDL-C105 ± 30TG121 ± 88TG121 ± 88LDL-p1392 ± 278LDL-p53 ± 40LDL-p53 ± 40LDL-p54 ± 40LDL-p53 ± 40LDL-p53 ± 40LDL-p54 ± 40LDL-p54 ± 40LDL-p54 ± 40LDL-p54 ± 40LDL-p<	Municipality population			
>50,000       53.8         Butuation level       12.8         No studies       47.6         High school-college       39.6         Bwit (kg/m <sup>2</sup> )       28.0 ± 5.2         124       7.8 ± 1.8         Hage score       7.8 ± 1.8         I-13       1-13         Hed diet score       7.8 ± 1.8         Low       42.0         Medium       34.5         High       23.5         High       23.5         FC       196 ± 40         JDL-C       105 ± 30         JDL-C       105 ± 30         HDL-C       52 ± 13         TG       121 ± 88         JDL-C       121 ± 88         JDL-C       121 ± 88         JDL-C       52 ± 13         JDL-C       121 ± 88         JDL-C       121 ± 88         JDL-C       121 ± 88         JDL-C       121 ± 88         JDL-P       1392 ± 278         JDL-P       53 ± 40	<10,000	18.4		
Education level       12.8         No studies       47.6         Basic       47.6         High school-college       39.6         BMI (kg/m <sup>2</sup> )       28.0±5.2       12.2-61.3         Med diet score       7.8±1.8       1-13         PHysical activity (IPAQ)       7.8±1.8       1-13         Low       42.0       42.0         Medium       34.5       42.0         High       23.5       42.0         TC       196±40       58-395         LDL-C       105±30       21-254         HDL-C       52±13       7-14         TG       121±88       17-2095         Furticle concentration ( <sup>1</sup> H-WIC) (mWIC)       121±88       358-2702         LDL-p       1392±278       358-2702         VLDL-p       53±40       12-619	10,000-50,000	27.8		
No studies       12.8         Basic       47.6         High school-college       39.6         BMI (kg/m <sup>2</sup> )       28.0 ± 5.2       12.2–61.3         Med diet score       7.8 ± 1.8       1–13         Physical activity (IPAQ)       1.22       1.22         Low       42.0       1.22         Medium       34.5       1.23         High       23.5       1.22         TC       196 ± 40       58–395         LDL-C       105 ± 30       21–254         HDL-C       52 ± 13       7–14         TG       121 ± 88       17–2095         Purticle concentration ( <sup>1</sup> H-WIC) (nWIC)       121 ± 88       358–2702         LDL-p       1392 ± 278       358–2702         VLDL-p       53 ± 40       12–619	>50,000	53.8		
Basic       47.6         High school-college       39.6         BMI (kg/m <sup>2</sup> )       28.0 ± 5.2       12.2 - 61.3         BMI (kg/m <sup>2</sup> )       7.8 ± 1.8       1-13         Ited diet score       7.8 ± 1.8       1-13         Ited diet score       42.0       1-13         Ited diet score       42.0       1-13         Medium       34.5       1-13         High       23.5       1-13         Ited lowering medication       3.3       1-13         Ited lowering medication       13.3       1-13         Ited lowering medication       13.3       21-254         Ited LoL-C       105 ± 30       21-254         Ited LoL-C       105 ± 30       21-254         Ited LoL-C       52 ± 13       7-14         Ited Concentration ( <sup>1</sup> H-WEW) (UWEW)       12-609       12-609         Ited LoL-P       1392 ± 278       358-2702         Ited LoL-P       53 ± 40       12-619	Education level			
High school-college       39.6         BMI (kg/m <sup>2</sup> )       28.0±5.2       12.2-61.3         Med diet score       7.8±1.8       1-13         Physical activity (IPAQ)       7.8±1.8       1-13         Low       42.0       42.0         Medium       34.5       1000000000000000000000000000000000000	No studies	12.8		
BMI (kg/m²) $28.0\pm5.2$ $12.2-61.3$ Med diet score $7.8\pm1.8$ $1-13$ Physical activity (IPAQ) $1.22-61.3$ $1-13$ Low $42.0$ $1.22-61.3$ Med diet score $7.8\pm1.8$ $1-13$ Physical activity (IPAQ) $1.22-61.3$ $1-13$ Low $42.0$ $1.22-61.3$ $1-13$ Medium $34.5$ $1.20-10000000000000000000000000000000000$	Basic	47.6		
Med diet score       7.8±1.8       1–13         Physical activity (IPAQ)       1       1         Low       42.0       1         Medium       34.5       1         High       23.5       1         Lowering medication       13.3       1         Standard lipid biomarkers (mg/dL)       196±40       58-395         LDL-C       105±30       21-254         HDL-C       52±13       7-14         TG       121±88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (mm/L)       1392±278       358-2702         VLDL-p       53±40       12-619	High school-college	39.6		
Physical activity (IPAQ)         Low       42.0         Medium       34.5         High       23.5         Lipid lowering medication       13.3         Standard lipid biomarkers (m/dL)       196 ± 40       58-395         LDL-C       105 ± 30       21-254         HDL-C       52 ± 13       7-14         TG       121 ± 88       17-2095         Particle concentration ( <sup>1</sup> H-NUR) (mNU/L)       LDL-p       358-2702         LDL-p       1392 ± 278       358-2702         VLDL-p       53 ± 40       12-619	BMI (kg/m <sup>2</sup> )		$28.0 \pm 5.2$	12.2-61.3
Low       42.0         Medium       34.5         High       23.5         Lipid lowering medication       13.3         Standard lipid biomarkers (mg/dL)       196 ± 40       58-395         LDL-C       196 ± 40       21-254         HDL-C       52 ± 13       7-14         TG       121 ± 88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (nmu/L)       1392 ± 278       358-2702         VLDL-p       53 ± 40       12-619	Med diet score		$7.8 \pm 1.8$	1-13
Medium       34.5         High       23.5         Lipid lowering medication       13.3         Standard lipid biomarkers (mg/dL)       196 ± 40       58-395         LDL-C       196 ± 40       21-254         HDL-C       52 ± 13       7-14         TG       121 ± 88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (nmU/L)       1392 ± 278       358-2702         VLDL-p       53 ± 40       12-619	Physical activity (IPAQ)			
High       23.5         Lipid lowering medication       13.3         Standard lipid biomarkers (mg/dL)       TC         TC       196 ± 40       58-395         LDL-C       105 ± 30       21-254         HDL-C       52 ± 13       7-14         TG       121 ± 88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (nmU/L)       1392 ± 278       358-2702         VLDL-p       53 ± 40       12-619	Low	42.0		
Lipid lowering medication       13.3         Standard lipid biomarkers (mg/dL)       TC         TC       196±40       58-395         LDL-C       105±30       21-254         HDL-C       52±13       7-14         TG       121±88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)       Just 278       358-2702         VLDL-p       53±40       12-619	Medium	34.5		
Standard lipid biomarkers (mg/dL)       TC       196±40       58-395         LDL-C       105±30       21-254         HDL-C       52±13       7-14         TG       121±88       17-2095         Particle concentration ( <sup>1</sup> H-NMR) (nmJ/L)       1392±278       358-2702         VLDL-p       53±40       12-619	High	23.5		
TC     196±40     58-395       LDL-C     105±30     21-254       HDL-C     52±13     7-14       TG     121±88     17-2095       Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)     1392±278     358-2702       LDL-p     1392±278     53±40     12-619	Lipid lowering medication	13.3		
LDL-C     105±30     21-254       HDL-C     52±13     7-14       TG     121±88     17-2095       Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)     1392±278     358-2702       VLDL-p     53±40     12-619	Standard lipid biomarkers (n	ng/dL)		
HDL-C     52±13     7-14       TG     121±88     17-2095       Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)     LDL-p     1392±278     358-2702       VLDL-p     53±40     12-619	TC		$196 \pm 40$	58-395
TG     121±88     17-2095       Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)     1392±278     358-2702       LDL-p     1392±278     358-2702       VLDL-p     53±40     12-619	LDL-C		$105 \pm 30$	21-254
Particle concentration ( <sup>1</sup> H-NMR) (nmol/L)           LDL-p         1392±278         358-2702           VLDL-p         53±40         12-619	HDL-C		$52 \pm 13$	7–14
LDL-p 1392±278 358-2702 VLDL-p 53±40 12-619	TG		$121\pm88$	17-2095
VLDL-p 53±40 12-619	Particle concentration ( <sup>1</sup> H-N	MR) (nmo	l/L)	
	LDL-p		$1392 \pm 278$	358-2702
HDL-p 28±5 6-56	VLDL-p		$53 \pm 40$	12-619
	HDL-p		$28 \pm 5$	6-56

**TABLE 1** Clinical characteristics and lipid values of the study sample (n = 4647).

Abbreviations: HDL-C, high-density lipoprotein cholesterol; HDL-p, HDL particles; LDL-C, low-density lipoprotein cholesterol; LDL-p, LDL particles; TC, total cholesterol; TG: triglycerides; VLDL-p, VLDL particles; <sup>1</sup>H-NMR, proton nuclear magnetic resonance.

profile and NMR, per each IQR increase in air pollutant concentrations. Replicating what was seen in the linear model, there was a strong negative association between the three air pollutants tested, and HDL-c. In the fully adjusted model, the odds of presenting low HDL-c (<40 mg/ dL), were 1.36 (95% CI 1.21-1.54) p<.001, 1.41 (95% CI 1.25-1.59) p<.001 and 1.31 (95% CI 1.18-1.44) p<.001 per each IQR increase in PM<sub>10</sub>, PM<sub>25</sub> and NO<sub>2</sub>. Again, this same trend was observed for the association between air pollutants and HDL-p, with multivariate ORs for presenting low HDL-p (<p25) of 1.23 (95% CI 1.09-1.37) *p* < .001, 1.23 (95% CI 1.10–1.37) *p* < .001 and 1.18 (95% CI 1.07–1.29) p=.001 per each IQR increase in PM<sub>10</sub>, PM<sub>25</sub> and NO<sub>2</sub>, respectively. In the logistic regression models, there was also a positive association between PM<sub>10</sub> and PM<sub>2.5</sub> concentrations and the odds of presenting higher LDL-p, with multivariate ORs for presenting LDL-p concentrations  $\geq p75$  of 1.24 (95% CI 1.11–1.39) p < .001 and 1.16 (95% CI 1.04–1.29) p=.007, per each IQR increase, respectively.

In the subgroup analysis, we found a significant interaction between sex and the association between  $PM_{10}$ and NO<sub>2</sub> and low HDL-p (*p* for interaction .008 and .034, respectively), with stronger associations in men. We also found a stronger association between NO<sub>2</sub> and low HDL-p in individuals with obesity (*p* for interaction .015) (Figure 1).

# 4 | DISCUSSION

In this nationwide sample representative of the adult population of Spain we found significant associations between exposure to various air pollutants and several standard and novel blood lipoprotein measures, pointing to a pro-atherogenic lipid profile in subjects exposed to a higher degree of pollution. In particular we found strong negative associations between  $PM_{10}$ ,  $PM_{2.5}$  and  $NO_2$  exposures, and both HDL-c and HDL-p concentrations both in linear and in logistic multivariate regression models. Additionally, we found a significant association between exposure to  $PM_{10}$  and  $PM_{2.5}$ , and

**TABLE 2** Descriptive statistics for air pollutants concentrations  $(\mu g/m^3)$  in the study sample.

	Percen	tile							
Pollutant	5th	25th	50th	75th	95th	IQR	Mean	Minimum	Maximum
$PM_{10}$	14.4	19.6	23.7	27.3	33.1	7.7	23.2	4.0	42.3
PM <sub>2.5</sub>	8.1	10.5	12.2	15.3	20.0	4.8	12.7	3.4	22.3
NO <sub>2</sub>	6.6	12.5	16.6	24.6	50.3	12.1	20.2	3.6	51.4

Abbreviations: IQR, interquartile range;  $NO_2$ , nitrogen dioxide;  $PM_{10}$ , particles with an aerodynamic diameter of less than 10 microns;  $PM_{2.5}$ , particles with an aerodynamic diameter of less than 2.5 microns.

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Standard lipid biomarkers	markers						
		TC		LDL-C		HDL-C		TG	
e $-17(-25, -1.0)$ $<001$ $-1.6(-27, -0.5)$ $004$ $-3.2(-41, -2.3)$ $<001$ $0.4(-14, 20)$ $0.01$ ivariate $-1.1(-19, -0.3)$ $013$ $-0.3(-16, 0.9)$ $590$ $-3.2(-41, -2.3)$ $<001$ $20(01, 3.9)$ $0$ ivariate $-1.1(-19, -0.3)$ $01$ $-0.3(-10, 0.1)$ $530$ $-3.2(-44, -2.3)$ $<001$ $10(-10, 2.9)$ $0$ ivariate $-0.6(-1.4, 0.3)$ $215$ $-0.3(-10, 0.1)$ $538$ $-3.2(-44, -2.3)$ $<001$ $10(-10, 2.9)$ $0$ ivariate $-0.6(-1.4, 0.3)$ $215$ $-0.3(-10, 0.2)$ $.118$ $-3.2(-43, -2.3)$ $<001$ $10(-10, 2.9)$ $.001$ ivariate $-1.8(-25, -1.2)$ $<001$ $-1.8(-23, -0.7)$ $<001$ $-1.5(-23, 0.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ $-1.5(-12, 2.1)$ $.001$ <		% change (95% CI)	d	% change (95% CI)	d	% change (95% CI)	d	% change (95% CI)	d
e $-1.7(-25, -1.0)$ $(001)$ $-1.6(-2.1, -0.2)$ $013$ $-0.3(-16, 0.0)$ $590$ $-3.2(-4.4, -2.3)$ $(001)$ $014(-14, 2.0)$ $0$ e $-11(-19, -0.2)$ $013$ $-0.3(-16, 0.0)$ $590$ $-3.2(-4.4, -2.3)$ $(001)$ $20(01, 39)$ $0$ wriate $-0.6(-14, 0.3)$ $215$ $-0.3(-10, 1.5)$ $628$ $-3.3(-4.3, -2.3)$ $(001)$ $10(-10, 2.9)$ $0$ wriate $-0.6(-14, 0.3)$ $215$ $-0.3(-10, 1.5)$ $628$ $-3.3(-4.3, -2.3)$ $(001)$ $10(-10, 2.9)$ $0$ wriate $-1.4(-22, -0.7)$ $<001$ $-1.8(-27, -0.9)$ $<001$ $-2.5(-1.2, 2.1)$ $0$ wriate $-1.4(-22, -0.7)$ $<001$ $-2.5(-13, 0.0)$ $0$ $-1.5(-23, 0.0)$ $0$ Farticle concentration (H-NMR)         Particle concentration (H-	PM <sub>10</sub>		500				500		Ľ
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Cruae	-1.7 (-2.5, -1.0)	100.>	-1.0 (-2.7, -0.2)	.004	-3.2 (-4,1, -2.3)	100.>	0.4 (-1.4, 2.0)	/00.
e $-11(-12, -03)$ $01$ $-08(-20, 04)$ $190$ $-30(-40, -21)$ $(00)$ $10(-10, 29)$ $30$ Initiate $-06(-14, 0.3)$ $215$ $-0.3(-10, 1.5)$ $628$ $-30(-40, -21)$ $(00)$ $10(-10, 29)$ $00$ Initiate $-18(-25, -12)$ $<001$ $-18(-23, -0.9)$ $<001$ $-27(-34, -12)$ $<001$ $-15(-29, 0.0)$ $0$ Initiate $-14(-22, -0.7)$ $<001$ $-09(-19, 0.2)$ $118$ $-27(-34, -19)$ $<001$ $-15(-12, 21)$ $0$ Initiate $-14(-22, -0.7)$ $<001$ $-27(-34, -12)$ $<001$ $-15(-12, 21)$ $0$ Initiate $-14(-22, -0.7)$ $<001$ $-16(-34, -12)$ $<001$ $-15(-12, 21)$ $0$ Initiate $-14(-22, -0.7)$ $<01$ $-16(-34, -12)$ $<001$ $-15(-12, 21)$ $0$ Keinage (95% (C)) $p$ $-27(-38, -23)$ $<001$ $-15(-12, 21)$ $0$ Keinage (95% (C)) $p$ $-27(-38, -23)$ $<001$ $-15(-12, 21)$	Multivariate	-1.1(-1.9, -0.2)	510.	-0.3(-1.6, 0.9)	066.	-5.5 (-4.5, -2.5)	100'>	2.0 (0.1, 3.9)	.037
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	PM <sub>2.5</sub>								
waiste $-0.6(-14, 0.3)$ $215$ $-0.3(-1.0, 1.5)$ $528$ $-33(-43, -2.3)$ $<001$ $28(09, 47)$ $0$ e $-1.8(-25, -1.2)$ $<001$ $-1.8(-27, -0.7)$ $<001$ $-1.5(-29, 0.0)$ $0$ wariate $-1.4(-22, -0.7)$ $<001$ $-0.7(-34, -1.9)$ $<001$ $-1.5(-29, 0.0)$ $0$ wariate $-1.4(-22, -0.7)$ $<001$ $-0.7(-34, -1.9)$ $<001$ $-1.5(-29, 0.0)$ $0$ Wariate $-1.4(-22, -0.7)$ $<001$ $-0.7(-34, -1.9)$ $<001$ $-1.5(-29, 0.0)$ $0$ Wariate $-1.4(-22, -0.7)$ $<001$ $-0.7(-34, -1.9)$ $<001$ $-1.5(-29, 0.0)$ $0$ Kariate $0.2(-0.6, 0.9)$ $7.3$ $\sqrt{UDL-p}$ $UDL$	Crude	-1.1(-1.9, -0.3)	.01	-0.8(-2.0, 0.4)	.190	-3.0(-4.0, -2.1)	<.001	1.0 (-1.0, 2.9)	.323
	Multivariate	-0.6(-1.4, 0.3)	.215	-0.3(-1.0, 1.5)	.628	-3.3 (-4.3, -2.3)	<.001	2.8 (0.9, 4.7)	.003
e $-1.8 (-25, -1.2)$ $<001$ $-2.7 (-3.4, -1.9)$ $<001$ $-1.5 (-29, 00)$ $0$ rariate $-1.4 (-22, -0.7)$ $<001$ $-0.9 (-1.9, 0.2)$ $.118$ $-2.7 (-3.4, -1.9)$ $<001$ $-1.5 (-2.9, 00)$ $.0$ Particle concentration ('H-NMR) $-1.4 (-22, -0.7)$ $<001$ $-0.5 (-1.2, 2.1)$ $.5$ Dataticle concentration ('H-NMR) $-1.4 (-22, -0.7)$ $<001$ $-0.5 (-1.2, 2.1)$ $.5$ Mouth $\overline{7}$ $\overline{7}$ $-3.0 (-3.8, -2.2)$ $<01$ $-1.5 (-2.9, 00)$ $.0$ Mouth $\overline{7}$ $\overline{7}$ $\overline{7}$ $\overline{7}$ $\overline{7}$ $\overline{7}$ $\overline{7}$ Mouth $\overline{7}$	$NO_2$								
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Crude	-1.8 (-2.5, -1.2)	<.001	-1.8(-2.7, -0.9)	<.001	-2.7 (-3.4, -1.9)	<.001	-1.5(-2.9,0.0)	.053
Particle concentration ('H-NMR)           LDL-p         HDL-p           LDL-p         VLDL-p         HDL-p $\frac{(DL-p)}{\%$ change (95% CI) $p$ $\frac{(DL-p)}{\%}$ $(DL$	Multivariate	-1.4(-2.2, -0.7)	<.001	-0.9(-1.9, 0.2)	.118	-3.0 (-3.8, -2.2)	<.001	-0.5(-1.2, 2.1)	.570
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Particle concentrs	ation ( <sup>1</sup> H-NMR)						
$\pi$ change (95% CI) $p$ $\pi$ change (95% CI) $\pi$ $\pi$ ( $\pi$ ( $\pi$ ) $\pi$		LDL-p		I	LDL-p			HDL-p	
e $0.2(-0.6, 0.9)$ .703 $1.1(-1.0, 3.2)$ .324 $-0.7(-1.3, 0.0)$ ivariate $0.6(-0.3, 1.4)$ .205 $1.9(-0.3, 4.1)$ .091 $-1.3(-2.0, -0.6)$ $<$ ivariate $0.4(-0.4, 1.2)$ .364 $1.0(-1.3, 3.2)$ .391 $-0.8(-1.5, -0.1)$ $<$ ivariate $0.6(-0.2, 1.5)$ .159 $1.9(-0.3, 4.1)$ .089 $-1.4(-2.1, -0.7)$ $<$ ivariate $0.6(0.0, 1.2)$ .068 $0.3(-1.3, 2.0)$ .703 $-0.5(-1.1, 0.0)$ ivariate $0.5(-0.2, 1.3)$ .155 $1.8(-0.1, 3.6)$ .059 $-0.5(-1.1, 0.0)$		% change (95% CI)		%	change (95% CI)	d		% change (95% CI)	d
le $0.2(-0.6, 0.9)$ .703 $1.1(-1.0, 3.2)$ .324 $-0.7(-1.3, 0.0)$ ivariate $0.6(-0.3, 1.4)$ .205 $1.9(-0.3, 4.1)$ .091 $-1.3(-2.0, -0.6)$ $-1.3(-2.0, -0.6)$ le $0.4(-0.4, 1.2)$ .364 $1.0(-1.3, 3.2)$ .391 $-0.8(-1.5, -0.1)$ ivariate $0.6(-0.2, 1.5)$ .159 $1.9(-0.3, 4.1)$ .089 $-1.4(-2.1, -0.7)$ le $0.5(-0.2, 1.3)$ .068 $0.3(-1.3, 2.0)$ .703 $-0.5(-1.1, 0.0)$ ivariate $0.5(-0.2, 1.3)$ .155 $1.8(-0.1, 3.6)$ .703 $-0.5(-1.1, 0.0)$	$PM_{10}$								
ivariate $0.6(-0.3, 1.4)$ $.205$ $1.9(-0.3, 4.1)$ $.091$ $-1.3(-2.0, -0.6)$ <le $0.4(-0.4, 1.2)$ $.364$ $1.0(-1.3, 3.2)$ $.391$ $-0.8(-1.5, -0.1)$ ivariate $0.6(-0.2, 1.5)$ $.159$ $1.9(-0.3, 4.1)$ $.089$ $-1.4(-2.1, -0.7)$ <	Crude	0.2(-0.6,0.9)	.703	1.1	l (-1.0, 3.2)	.324		-0.7(-1.3, 0.0)	.049
le $0.4(-0.4, 1.2)$ $.364$ $1.0(-1.3, 3.2)$ $.391$ $-0.8(-1.5, -0.1)$ ivariate $0.6(-0.2, 1.5)$ $.159$ $1.9(-0.3, 4.1)$ $.089$ $-1.4(-2.1, -0.7)$ le $0.6(0.0, 1.2)$ $.068$ $0.3(-1.3, 2.0)$ $.703$ $-0.5(-1.1, 0.0)$ ivariate $0.5(-0.2, 1.3)$ $.155$ $1.8(-0.1, 3.6)$ $.059$ $-1.1(-1.6, -0.5)$ observable on the second s	Multivariate	0.6(-0.3,1.4)	.205	1.5	) (-0.3, 4.1)	.091		-1.3 (-2.0, -0.6)	<.001
ide $0.4(-0.4, 1.2)$ $.364$ $1.0(-1.3, 3.2)$ $.391$ $-0.8(-1.5, -0.1)$ Itivariate $0.6(-0.2, 1.5)$ $.159$ $1.9(-0.3, 4.1)$ $.089$ $-1.4(-2.1, -0.7)$ ide $0.6(0.0, 1.2)$ $.068$ $0.3(-1.3, 2.0)$ $.703$ $-0.5(-1.1, 0.0)$ Itivariate $0.5(-0.2, 1.3)$ $.155$ $1.8(-0.1, 3.6)$ $.059$ $-1.1(-1.6, -0.5)$	$PM_{2.5}$								
Itivariate $0.6 (-0.2, 1.5)$ $.159$ $1.9 (-0.3, 4.1)$ $.089$ $-1.4 (-2.1, -0.7)$ <ide $0.6 (0.0, 1.2)$ $.068$ $0.3 (-1.3, 2.0)$ $.703$ $-0.5 (-1.1, 0.0)$ Itivariate $0.5 (-0.2, 1.3)$ $.155$ $1.8 (-0.1, 3.6)$ $.059$ $-1.1 (-1.6, -0.5)$	Crude	0.4(-0.4, 1.2)	.364	1.(	) (-1.3, 3.2)	.391		$-0.8\left(-1.5,-0.1 ight)$	.018
ide $0.6 (0.0, 1.2)$ $.068$ $0.3 (-1.3, 2.0)$ $.703$ $-0.5 (-1.1, 0.0)$ Itivariate $0.5 (-0.2, 1.3)$ $.155$ $1.8 (-0.1, 3.6)$ $.059$ $-1.1 (-1.6, -0.5)$	Multivariate	0.6(-0.2, 1.5)	.159	1.5	) (-0.3, 4.1)	.089		-1.4(-2.1, -0.7)	<.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$NO_2$								
0.5(-0.2, 1.3)    .155    1.8(-0.1, 3.6)    .059    -1.1(-1.6, -0.5)	Crude	0.6(0.0,1.2)	.068	0.2	3 (-1.3, 2.0)	.703		-0.5(-1.1, 0.0)	.040
	Multivariate	0.5(-0.2, 1.3)	.155	1.5	1.8 (-0.1, 3.6)	.059		-1.1 (-1.6, -0.5)	<.001

TABLE 3 Associations between air pollutants (per IQR concentrations increase) and blood lipid levels.

6 of 11 WILEY TABLE 4 Odd ratios (OR) for presenting lipid abnormalities per interquartile range (IQR) increase in air pollutants concentrations.

	Stand	ard lipid bio	marker	s									
	TC≥240 mg/dL			LDL-	LDL-C≥160 mg/dL			HDL-C < 40 mg/dL			Triglycerides≥200 mg/dL		
	OR	95% CI	р	OR	95% CI	р	OR	95% CI	р	OR	95% CI	р	
PM <sub>10</sub>													
Crude	0.94	0.85-1.05	.282	0.99	0.82-1.20	.952	1.29	1.17-1.43	.000	0.96	0.85-1.08	.489	
Multivariate	1.02	0.90-1.16	.718	1.10	0.87-1.37	.428	1.36	1.21-1.54	.000	0.97	0.83-1.12	.655	
PM <sub>2.5</sub>													
Crude	1.00	0.89-1.13	.958	1.07	0.87-1.31	.521	1.33	1.20-1.47	.000	0.94	0.82-1.07	.353	
Multivariate	1.07	0.94-1.22	.314	1.16	0.92-1.46	.198	1.41	1.25-1.59	.000	0.95	0.82-1.11	.542	
NO <sub>2</sub>													
Crude	0.93	0.85-1.02	.139	0.97	0.83-1.14	.975	1.23	1.14-1.32	.000	0.91	0.82-1.01	.073	
Multivariate	0.99	0.88-1.11	.853	1.11	0.91-1.36	.285	1.31	1.18-1.44	.000	0.96	0.84-1.10	.558	
	Pa	rticle concer	ntration	( <sup>1</sup> H-NI	MR)								
	LD	LDL-p≥p75			VLDL	-p≥p75			HDI	L-p < p25			
	OF	95%	CI	р	OR	<b>95</b> %	% CI	р	OR	9	5% CI	р	
$PM_{10}$													
Crude	1.1	5 1.06-	1.26	.002	1.03	0.9	4–1.12	.578	1.12	1	.03-1.23	.011	
Multivariate	1.2	4 1.11-	1.39	.000	1.08	0.9	6–1.21	.188	1.23	1	.09–1.37	.000	
PM <sub>2.5</sub>													
Crude	1.1	2 1.02-	1.23	.016	1.02	0.9	3–1.12	.631	1.13	1	.03-1.24	.007	
Multivariate	1.1	6 1.04-	1.29	.007	1.09	0.9	7–1.21	.144	1.23	1	.10–1.37	.000	
NO <sub>2</sub>													
Crude	1.0	8 1.01-	1.16	.023	0.99	0.9	2-1.06	.741	1.10	1	.03–1.17	.007	
Multivariate	1.1	1 1.02-	1.22	.018	1.05	0.9	5–1.15	.334	1.18	1	.07–1.29	.001	


*Note*: ORs. 95% CI and *p* values were calculated by logistic regression per interquartile range (IQR) increase in air pollutants concentrations (PM<sub>10</sub>: 7.7 µg/m<sup>3</sup>, PM<sub>2.5</sub>: 4.8 µg/m<sup>3</sup>, NO<sub>2</sub>: 12.1 µg/m<sup>3</sup>). In bold: % changes with *p* values < .007 (alpha .05 corrected by Bonferroni = .05/7). Multivariate model: adjusted to age, sex, BMI, smoking status, alcohol intake, education level, MedScore, IPAQ, municipality population, ambient temperature and lipid lowering medication. Abbreviations: HDL-C, high-density lipoprotein cholesterol; HDL-p, HDL particles; LDL-C, low-density lipoprotein cholesterol; HDL-p, LDL particles; NO<sub>2</sub>, nitrogen dioxide; PM<sub>10</sub>, particles with an aerodynamic diameter of less than 10 microns; PM<sub>2.5</sub>, particles with an aerodynamic diameter of less than 2.5 microns; TC, total cholesterol; TG, triglycerides; VLDL-p, VLDL particles; <sup>1</sup>H-NMR, proton nuclear magnetic resonance.

higher LDL-p concentrations (≥p75), although the associations between air pollutants and the standard LDL-c measures were null.

These findings are in line with previous studies suggesting that air pollution might negatively impact blood lipids in the general population,<sup>6-24</sup> and may be a potential contributor to air pollution-related CVD risk. In fact, low HDL-c is a well-established atherosclerotic CVD risk factor,<sup>34</sup> whereas lower HDL and higher LDL particle numbers have also been associated with increasing cardiovascular events.<sup>42-44</sup>

Interestingly, although the relationship of the exposure to different air pollutants with standard lipid biomarkers has been widely studied, to the best our knowledge, only two previous studies have assessed associations with particle concentration measures. Bell et al.<sup>9</sup> examined the relationship between air pollution and both HDL-c and HDL-p, in 6654 men and women free of prevalent clinical CVD, participants in the Multi-Ethnic Study of Atherosclerosis Air Pollution study (MESA Air). A  $5 \mu g/m^3$  higher PM<sub>2.5</sub> was associated with lower HDL-p (-0.64 µmol/L [95% CI -1.01, -0.26]), but not HDL-c (-0.05 mg/dL [95% CI -0.82, 0.71]). Mc-Guinn et al.<sup>13</sup> studied linear associations to estimate change in lipoprotein levels with each  $\mu g/m^3$  increase in annual average PM<sub>2.5</sub> in 6587 patients who had a cardiac catheterization in Duke University between 2001 and 2010 (CATHGEN study). The percent change from the mean outcome level was 2.00% (95% CI 1.38%, 2.64%) for total LDL-p. However, the associations between air pollution and HDL particle concentrations in this study were inconsistent. This is in contrast to the findings





**FIGURE 1** Logistic regression analyses between  $PM_{2.5}$ ,  $PM_{10}$  and  $NO_2$  exposures and HDL-c <40 mg/dL, HDL-p <p25 and LDL-p  $\geq$  p75 in different population subgroups.

reported by Bell et al. in the MESA Air study<sup>9</sup> and to our results in di@bet.es, which indicate strong negative associations between air pollutants and HDL markers. Of note, the CATHGEN study sample consisted of patients who underwent cardiac catheterization, who may represent a highly selective population, while the MESA Air and the di@bet.es study populations may be more generalizable to the general background population.

Although the observed differences in blood lipids found in our study may seem small, it is of note that, as

pointed out by Bell et al.,<sup>9</sup> the magnitude of the decrease of HDL-c and HDL-p we have observed (between -3.0% and -3.3% decrease in HDL-c and -1.1% to -1.4% decrease in HDL-p per IQR increase in air pollutants concentration), can be compared to the effect of smoking on these measurements as observed in smoking cessation studies (2.4 mg/dL and 1.0 µmol/L change on HDL-c and HDL-p, respectively).<sup>45</sup>

On the other hand, exposure to air pollution has also been shown to induce the development of dysfunctional HDL resulting in alteration of its atheroprotective capacities,<sup>46,47</sup> which may contribute to atherosclerosis progression beyond the total lipoprotein concentrations measured in our study.

The apparently counterintuitive negative association between air pollutants and TC observed is of small magnitude and could be explained by the contribution of HDL-c to the TC levels, which was significantly reduced when associated with higher exposures. In line with this, no associations with LDL-c levels in the multivariate analyses were found. This apparently benign effect of air pollutants in the standard LDL-c measures was however accompanied by a significant association between higher exposures to  $PM_{10}$  and  $PM_{2.5}$ , and higher LDL-p concentrations ( $\geq p75$ ). LDL-p has been found to be a better predictor of CVD than LDL-c, especially in individuals with LDL-p/LDL-c discordance.<sup>28,29,48</sup> So again, these associations could be regarded as pro-atherogenic. In subgroup analyses, we found stronger associations between PM<sub>10</sub> and NO<sub>2</sub> and low HDL-p in men, and between NO<sub>2</sub> and low HDL-p in individuals with obesity, suggesting that these subgroups may be more susceptible. A stronger susceptibility in overweight-obese individuals is consistent with Sørensen et al.,<sup>6</sup> Yang et al.,<sup>10</sup> Kim et al.,<sup>12</sup> Mao et al.,<sup>16</sup> Zhang et al.<sup>22</sup> and Kim et al.<sup>19</sup> among others. Both air pollution exposure and overweight/obesity are associated with higher systemic inflammation<sup>2,49</sup> which may explain an interplay of these factors. The modification effects of sex in previous studies have been mixed and harder to interpret.

The underlying mechanisms explaining the effect of air pollutants on lipids have not been fully elucidated. The main hypothesis is that the oxidative stress and systemic inflammation caused by inhaled air pollution could induce adverse lipid metabolism and lipid oxidation.<sup>50,51</sup> Air pollutants have also been found to cause DNA methylation of genes related to lipid metabolism.<sup>52</sup> Further studies are warranted to clarify the full spectrum of these mechanisms.

Our study has several strengths, including the large population-based design and the inclusion of advanced lipoprotein measures, as well as other extensive individuallevel data of clinical, demographic and lifestyle variables, which allowed us to perform a complete multivariate adjustment of the data. Our nationwide perspective, allows us to extrapolate our results more widely than local or regional studies, increasing the public health implications of the findings.

The limitations of our study include its observational cross-sectional nature; so that we cannot establish causal associations or exclude residual confounding in the relation between air pollutants and lipids. Also, we used ambient outdoor measurements modelled at the residential addresses of the participants as a proxy for exposure to air pollution, whereas no other relevant information such as time–activity patterns, proximity to main roads, occupational exposures or personal monitoring data was available. Exposure measurement error is possible when using modelled pollutant levels and this could, in fact, have attenuated our effect estimates. Finally, our exposure models were developed based on yearly exposures to air pollutants, whereas more refined measures to look at different lags were not available.

#### 5 | CONCLUSIONS

In summary, our study, in keeping with previous data, suggests a deleterious effect of the exposure to air pollutants on blood lipids, in the general population of Spain. Our results reinforce the need for improving air quality as much as possible to decrease the risk of atherosclerosis in our population, as the lipid changes observed in our study may be a potential contributor to air pollution-related CVD risk.

#### AUTHOR CONTRIBUTIONS

Conception and design: G.R.M and J.R. Acquisition of epidemiological data: C.M.A., E.G.E., S.G.S., A.C.P., L.C., E.D., E.M., J.F.N., S.G., J.G., F.J.C., S.V. and G.R.M. tandard biochemical samples management: W.O.B. and G.R.M. Liposcale<sup>®</sup> samples management and analyses: J.R., N.A. and M.G. Air pollution modelling: M.G.V., J.L.G., M.T., V.G. and F.M.L. Creation of new software used in the work: J.L.G.G and G.A.V. Analysis and interpretation of data: S.V. J.C.V. and G.R.M. Drafting the article: S.V., V.K.D.G. and G.R.M. All authors revised and approved the final manuscript.

#### ACKNOWLEDGEMENTS

The di@bet.es project is a collaborative study with various phases and sub-projects in which a large number of researchers and technicians have collaborated, to whom we are indebted. Our profound appreciation goes to the primary care managers and personnel of the participating health centres, to all the fieldworkers, nurses and technicians and to the study participants for their altruistic participation.

# NILEY

# FUNDING INFORMATION

CIBERDEM (Ministerio de Economía, Industria y Competitividad-ISCIII), Ministerio de Sanidad, Servicios Sociales e Igualdad-ISCIII, Instituto de Salud Carlos III (PI17/02136, PI20/01322), European Regional Development Fund (ERDF) 'A way to build Europe'. GRM belongs to the regional Nicolás Monardes research program of the Consejería de Salud (RC-0006-2016; Junta de Andalucía, Spain). VKDG is recipient of a 'Rio Hortega' research contract (CM21/00214, Instituto de Salud Carlos III). S.V.H. was supported by an intensification research program (INT21/00037, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER). Funding for open access charge: Universidad de Málaga/CBUA.

## CONFLICT OF INTEREST STATEMENT

N.A. is stock owner of Biosfer Teslab and has a patent on the method for lipoprotein profiling described in the present manuscript. The other authors declare that they have no competing financial interests related to this manuscript.

## ORCID

Sergio Valdés D https://orcid.org/0000-0001-8623-4331 *Viyey Doulatram-Gamgaram* bhttps://orcid. org/0000-0002-0178-0040 *Cristina Maldonado-Araque* **https://orcid.** org/0000-0002-3452-3489 Eva García-Escobar 💿 https://orcid. org/0000-0002-0134-3473 Joan Girbés D https://orcid.org/0000-0002-1665-4549 Gemma Rojo-Martínez, D https://orcid. org/0000-0003-2179-2134

# REFERENCES

- 1. WHO. Ambient (Outdoor) Air Pollution Key Facts. World Health Organization; 2022. Accessed October 3, 2023. https://www. who.int/news-room/fact-sheets/detail/ambient-(outdoor)-airquality-and-health
- 2. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation. 2010;121:2331-2378.
- 3. Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;11:627-642.
- 4. Rajagopalan S, Al-Kindi SG, Brook RD. Air pollution and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2018;17:2054-2070.
- 5. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol. 2020;10:656-672.
- 6. Sørensen M, Hjortebjerg D, Eriksen KT, et al. Exposure to longterm air pollution and road traffic noise in relation to cholesterol: a cross-sectional study. Environ Int. 2015;85:238-243.

- 7. Shanley RP, Hayes RB, Cromar KR, Ito K, Gordon T, Ahn J. Particulate air pollution and clinical cardiovascular disease risk factors. Epidemiology. 2016;27(2):291-298.
- 8. Yitshak-Sade M, Kloog I, Liberty IF, Schwartz J, Novack V. The association between air pollution exposure and glucose and lipids levels. J Clin Endocrinol Metab. 2016;101(6):2460-2467.
- 9. Bell G, Mora S, Greenland P, Tsai M, Gill E, Kaufman JD. Association of air pollution exposures with high-density lipoprotein cholesterol and particle number: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(5):976-982.
- 10. Yang BY, Bloom MS, Markevych I, et al. Exposure to ambient air pollution and blood lipids in adults: the 33 Communities Chinese Health Study. Environ Int. 2018;119:485-492.
- 11. Gaio V, Roquette R, Dias CM, Nunes B. Ambient air pollution and lipid profile: systematic review and meta-analysis. Environ Pollut. 2019;254:113036.
- 12. Kim JS, Chen Z, Alderete TL, et al. Associations of air pollution, obesity and cardiometabolic health in young adults: the meta-AIR study. Environ Int. 2019;133:105180.
- 13. McGuinn LA, Schneider A, McGarrah RW, et al. Association of long-term PM2.5 exposure with traditional and novel lipid measures related to cardiovascular disease risk. Environ Int. 2019:122:193-200.
- 14. Wu XM, Broadwin R, Basu R, et al. Associations between fine particulate matter and changes in lipids/lipoproteins among midlife women. Sci Total Environ. 2019;654:1179-1186.
- 15. Gui ZH, Yang BY, Zou ZY, et al. Exposure to ambient air pollution and blood lipids in children and adolescents: a national population-based study in China. Environ Pollut. 2020:266:115422.
- 16. Mao S, Li S, Wang C, et al. Is long-term PM1 exposure associated with blood lipids and dyslipidemias in a Chinese rural population? Environ Int. 2020;138:105637.
- 17. Mao S, Chen G, Liu F, et al. Long-term effects of ambient air pollutants to blood lipids and dyslipidemias in a Chinese rural population. Environ Pollut. 2020;256:113403.
- 18 Shin WY, Kim JH, Lee G, et al. Exposure to ambient fine particulate matter is associated with changes in fasting glucose and lipid profiles: a nationwide cohort study. BMC Public Health. 2020;20:430.
- 19. Kim HJ, Kwon H, Yun JM, Cho B, Park JH. Interaction between visceral adiposity and ambient air pollution on LDL cholesterol level in Korean adults. Int J Obes (Lond). 2021;45:547-554.
- 20. Li J, Yao Y, Xie W, et al. Association of long-term exposure to PM<sub>2.5</sub> with blood lipids in the Chinese population: findings from a longitudinal quasi-experiment. Environ Int. 2021;151:106454.
- 21. Wang L, Chen G, Pan Y, et al. Association of long-term exposure to ambient air pollutants with blood lipids in Chinese adults: the China multi-ethnic cohort study. Environ Res. 2021;1977:111174.
- Zhang K, Wang H, He W, et al. The association between am-22. bient air pollution and blood lipids: a longitudinal study in Shijiazhuang, China. Sci Total Environ. 2021;752:141648.
- 23. Zhang W, Liu J, Hu D, et al. Joint effect of multiple air pollutants on lipid profiles in obese and normal-weight young adults: the key role of ozone. Environ Pollut. 2022;292:118247.
- 24. Kim KN, Ha B, Seog W, Hwang IU. Long-term exposure to air pollution and the blood lipid levels of healthy young men. Environ Int. 2022;161:107119.

10 of 11

13652362, 0, Downloaded from https://anlinelibrary.wiley.com/doi/10.1111/cei.14101 by Cbua-Consorcio De Bibliotecas, Wiley Online Library on [16/10/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms -and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons Licens

- Pichler G, Amigo N, Tellez-Plaza M, et al. LDL particle size and composition and incident cardiovascular disease in a South-European population: the Hortega-Liposcale follow-up study. *Int J Cardiol.* 2018;264:172-178.
- Würtz P, Raiko JR, Magnussen CG, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. *Eur Heart J.* 2012;33:2307-2316.
- Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDLrelated measures and future coronary events. *Circulation*. 2014;129:553-561.
- 28. Tehrani DM, Zhao Y, Blaha MJ, et al. Discordance of lowdensity lipoprotein and high-density lipoprotein cholesterol particle versus cholesterol concentration for the prediction of cardiovascular disease in patients with metabolic syndrome and diabetes mellitus (from the multi-ethnic study of atherosclerosis [MESA]). *Am J Cardiol.* 2016;117:1921-1927.
- Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence. *Circulation*. 2018;138:2330-2341.
- Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. *Diabetologia*. 2012;55:88-93.
- World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310:2191-2194.
- Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J Nutr.* 2011;141:1140-1145.
- International Physical Activity Questionnaire. Accessed October 3, 2023. https://sites.google.com/view/ipaq
- 34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA*. 2001;285:2486-2497.
- Mallol R, Amigó N, Rodríguez MA, et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. *J Lipid Res.* 2015;56:737-746.
- Menut L, Bessagnet B, Khvorostyanov D, et al. CHIMERE 2013: a model for regional atmospheric composition modelling. *Geosci Model Dev.* 2013;6:981-1028.
- Vivanco MG, Palomino I, Vautard R, et al. Multi-year assessment of photochemical air quality simulation over Spain. *Environ Model Softw.* 2009;24:63-73.
- Vivanco MG, Azula O, Palomino I, Martín F. Evaluating the impact of resolution on the predictions of an air quality model over Madrid area (Spain). In: Murgante B, Borruso G, Lapucci A, eds. *Geocomputation, Sustainability and Environmental Plan Theory*. Springer; 2011:145-162.
- Martín F, Palomino I, Vivanco MG. Combination of measured and modelling data in air quality assessment in Spain. *Int J Environ Pollut*. 2012;49:36-44.

- 40. Spanish National Meteorological Agency. Accessed October 3, 2023. http://www.aemet.es
- 41. Directive 2008/50/EC of the European Parliament and of the Council of 21 May 2008 on ambient air quality and cleaner air for Europe. Accessed October 3, 2023. https://eur-lex.europa. eu/eli/dir/2008/50/2015-09-18
- 42. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA). *Atherosclerosis*. 2007;192:211-217.
- 43. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. *Circulation*. 2013;128:1189-1197.
- Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012;60:508-516.
- 45. Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. *Am Heart J.* 2011;161:145-151.
- Mathew AV, Yu J, Guo Y, et al. Effect of ambient fine particulate matter air pollution and colder outdoor temperatures on highdensity lipoprotein function. *Am J Cardiol.* 2018;122:565-570.
- Li J, Zhou C, Xu H, et al. Ambient air pollution is associated with HDL (high-density lipoprotein) dysfunction in healthy adults. *Arterioscler Thromb Vasc Biol.* 2019;39:513-522.
- Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between lowdensity lipoprotein cholesterol and particle number. *J Clin Lipidol.* 2011;5:105-113.
- Weichenthal S, Hoppin JA, Reeves F. Obesity and the cardiovascular health effects of fine particulate air pollution. *Obesity*. 2014;22:1580-1589.
- Chen T, Jia G, Wei Y, Li J. Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice. *Toxicol Lett.* 2013;223:146-153.
- Li R, Navab M, Pakbin P, et al. Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice. *J Lipid Res.* 2013;54:1608-1615.
- 52. Li H, Chen R, Cai J, Cui X, Huang N, Kan H. Short-term exposure to fine particulate air pollution and genome-wide DNA methylation: a randomized, double-blind, crossover trial. *Environ Int.* 2018;120:130-136.

**How to cite this article:** Valdés S, Doulatram-Gamgaram V, Maldonado-Araque C, et al. Association between exposure to air pollution and blood lipids in the general population of Spain. *Eur J Clin Invest.* 2023;00:e14101. doi:10.1111/eci.14101